Declining HIV/AIDS mortality in New York City

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 1, 1999, Pages 59-64

  Chiasson, Mary Ann ^b   Berenson, Louise ^d   Li, Wenhui ^d   Schwartz, Steven ^d   Singh, Tejinder ^d   Forlenza, Susan ^d   Mojica, Benjamin A ^d   Hamburg, Margaret A ^a,c  

^a New York City   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^d NONE

Author keywords

AIDS; HIV; Mortality; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; EPIDEMIC; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; UNITED STATES; URBAN AREA; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 0033135558     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199905010-00008     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 1997;9:9.
2. Lehner T, Chiasson MA. AIDS the changing epidemic. In Lowe C, ed. New York City Department of Health summary of reportable diseases and conditions, 1995. City Health Information 1996;15: 2-5.
3. Tu XM, Meng X-L, Pagano M. Survival differences and trends in patients with AIDS in the United States. J Acquir Immune Defic Syndr 1993;6:1150-6.
4. Osmond D, Charlebois E, Lang W, Shiboski S, Moss A. Changes in survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;271:1083-7.
5. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-6.
6. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City. The experience of the first decade of the epidemic. Am J Epidemiol 1994;139:351-61.
7. National Center for Health Statistics. Vital statistics, instructions for classifying the underlying cause of death. In NCHS instruction manual: part 2a. Hyattsville, MD: Public Health Service, published annually.
8. National Center for Health Statistics. Vital statistics of the United States, 1987, vol 2 (Mortality), part A. Washington, DC: Public Health Service, 1990.
9. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(No. RR-17):1-19.
10. New York City Department of Health. AIDS as a cause of death New York City, 1983-1995. New York: New York City Department of Health, 1996.
11. New York City Department of Health. The City of New York Summary of Vital Statistics 1994. New York: New York City Department of Health, 1995.
12. Ventura SJ, Anderson RN, Martin JA, Smith BL. Births and deaths: preliminary data for 1997, vol 47, no. 4. Hyattsville, MD: National Center for Health Statistics, 1998.
13. State of New York Department of Health. AIDS in New York State. Albany, NY: State of New York Department of Health, 1996.
14. Centers for Disease Control and Prevention. Recommendation for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994; 43(No. RR-12):1-21.
15. Chiasson MA, Berenson L, Li W, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City. Presented at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., 1997.
16. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
17. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:161-72.
18. The Delta Coordinating Committee. Delta: a randomized double-blind, controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine alone in HIV-infected individuals. Lancet 1996;348:283-91.
19. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy In HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
20. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
21. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
22. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
23. Hogg RS, O Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
24. Wong T, Reggy A, Chiasson M, et al. Protease inhibitors are associated with declining AIDS deaths in New York City. Presented at the XII World AIDS Conference, Geneva, 1998.